cb-839

NSCLC

Calithera Biosciences, IncPhase 1/2Dormant

CC

44/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 65/ 100

Competitive context

112 Active assets in the NSCLC cohort.

Asset / Sponsor	Phase	Rating
Dacomitinib Pfizer	Phase 4	BB
Penpulimab Yang Fan, MD	Phase 4	BB
Adebrelimab Peking University Cancer Hospital & Institute	Phase 3	BB
Fruquintinib Immunitas Therapeutics	Phase 3	BB
Rezivertinib The First Affiliated Hospital of Guangzhou Medical University	Phase 3	BB

View all 50 →

Same molecule, other indications

cb-839 is also rated in:

KRAS Gene MutationDormant

CCC

Indicative ·

52 / 100

CRCDormant

CCC

Indicative ·

48 / 100

Waldenstrom's Macroglobulinemia (WM)Dormant

CC

Indicative ·

47 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.